Velabs has pioneered the use of droplet microfluidics for the screening of antibodies that do not just bind to a drug target, but rather modulate its function.
Velabs technology is based on the direct screening of B-cell repertoires from mice and humans, which offers manifold advantages:
Velabs primarily aims at partnering with pharma companies in order to shorten the usual delay in preclinical hit generation and validation from several months or years to significantly shorter times.
Any partnering process with Velabs will speed up the discovery of efficient antibodies with almost no side effects.
Christoph Antz, Ph.D.
Christoph A. Merten, Ph.D.
Christoph is a principal investigator at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany.
Anna Pryszlak, Ph.D.
Anna is a researcher specialized in medical biotechnology with a strong background in microbiology and microfluidics.
Anja is a research associate with experience in lab management and a background in cell-, cancer- and microbiology.
Nachiket Shembekar, Ph.D.
Christian Leist, Ph.D. ETH Ing. Biotech.
Prof. Hans-Georg Rammensee, Ph.D.
Hans-Georg Rammensee was appointed Chair of the Department of Immunology at the University of Tübingen in 1996, after spending three years as Head of the Tumor-Virus-Immunology Section of the German Cancer Research Center (DKFZ) in Heidelberg.
Jesper Zeuthen, Ph.D.
Jesper has published more than 200 scientific publications and is an inventor on several patents.